VTRS · Earnings call · 2026Q2T · Full report

Operating Expense Trends

Viatris Inc · 2026-08-06 · Importance 50 · Surprise 58

Operating expenses declined as a percentage of revenue in the second quarter. Management attributed the improvement to SG&A discipline and savings from the enterprise-wide strategic review. R&D spending remained in line with expectations, primarily reflecting the Phase III selatogrel and cenerimod programs. Cost containment helped adjusted EBITDA grow at approximately twice the rate of revenue in the first half.

Key facts

• Adjusted EBITDA grew at about twice the rate of revenue in the first half of 2026 driven largely by cost containment measures
• Operating expenses declined as a percentage of total revenues versus prior year due in part to SG&A discipline and savings from enterprise-wide strategic review
• R&D investment progressed in line with expectations and was driven primarily by Phase III programs for selatogrel and cenerimod